On April 3, 2026, Denali Therapeutics Inc. announced the termination of its Collaboration Agreement with Takeda Pharmaceutical Company Limited regarding the co-development and co-commercialization of DNL593, an investigational therapy for frontotemporal dementia. The decision to terminate the agreement was communicated through a written notice from Takeda, citing strategic considerations rather than concerns related to efficacy or safety data. This termination will take effect 60 days from the notice date, allowing Denali to regain full rights to the DNL593 program and its associated intellectual property. Following the termination, Denali will not have any further financial obligations to Takeda. The company plans to continue the clinical development of DNL593, which utilizes its proprietary TransportVehicle technology to deliver progranulin to the brain. Results from an ongoing Phase 1/2 study in patients with FTD-GRN are expected by the end of 2026. Denali's CEO, Ryan Watts, expressed confidence in the scientific rationale behind DNL593 and the data generated thus far, emphasizing the importance of advancing the therapy independently. The termination of this collaboration may have implications for Denali's operational execution and strategy outlook, as it seeks to navigate the complexities of drug development in the competitive biotechnology landscape.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.